- Home
- MESO
MESO
Mesoblast Limited
as 01-21-2025 4:00pm EST
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.
| Founded: | 2004 | Country: | Australia |
| Employees: | N/A | City: | N/A |
| Market Cap: | 2.0B | IPO Year: | N/A |
| Target Price: | $13.50 | AVG Volume (30 days): | 828.2K |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.09 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.72 - $22.00 | Next Earning Date: | 02-28-2025 |
| Revenue: | $5,902,000 | Revenue Growth: | -21.32% |
| Revenue Growth (this year): | 65.99% | Revenue Growth (next year): | 425.77% |
Latest Mesoblast Limited News
MESO Breaking Stock News: Dive into MESO Ticker-Specific Updates for Smart Investing
Zacks
19 days ago
MESO Stock Surges 80% in a Month After FDA Approval of GVHD Drug
Simply Wall St.
19 days ago
Exploring 3 High Growth Tech Stocks In Australia
Zacks
a month ago
What Awaits These 4 Biotech Stocks That More Than Doubled in 2024
Zacks
a month ago
MESO Stock Up as FDA Approves Ryoncil for Graft Versus Host Disease
Pharmaceutical Technology
a month ago
FDA approves Mesoblast’s Ryoncil for SR-aGvHD treatment
Benzinga
a month ago
Mesoblast's Cell Therapy Treatment For Graft Versus Host Disease Gets FDA Approval, Stock Surges
MT Newswires
a month ago
Mesoblast Says Ryoncil Receives FDA Approval for Acute Graft Versus Host Disease; Shares Rise Pre-Bell
Investor's Business Daily
a month ago
Top-Notch Biotech Mesoblast Skyrockets 29% On Immune Condition Approval
Compare MESO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MESO Mesoblast Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.